LITE DEPALMA GREENBERG & RIVAS, LLC
Allyn Z. Lite
Michael E. Patunas
Two Gateway Center, 12th Floor
Newark, New Jersey 07102
(973) 623-3000

Attorneys for Plaintiffs Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc.

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

TEVA PHARMACEUTICAL INDUSTRIES LTD. and TEVA PHARMACEUTICALS USA, INC.,	:	
Plaintiffs	:	Civil Action No.
v.	:	
RANBAXY LABORATORIES LIMITED and RANBAXY PHARMACEUTICALS INC.,	:	
Defendants.	:	

COMPLAINT FOR DECLARATORY JUDGMENT

For their Complaint against Defendants Ranbaxy Laboratories Limited and Ranbaxy Pharmaceuticals, Inc. (collectively, "Defendants"), Plaintiffs Teva Pharmaceutical Industries Ltd. ("Teva Ltd.") and Teva Pharmaceuticals USA, Inc. ("Teva USA"; collectively, "Plaintiffs") allege as to their own acts, and on information and belief as to the acts of others, as follows:

THE PARTIES

1. Teva Ltd. is a corporation organized under the laws of Israel, and maintains its principal place of business at 5 Basel Street, Petah Tiqva 49131, Israel.

2. Teva USA is a Delaware corporation with its principal place of business located at 1090 Horsham Road, North Wales, Pennsylvania, 19454-1090. Teva USA is a wholly-owned subsidiary of Teva Ltd.

3. On information and belief, Defendant Ranbaxy Laboratories Limited is an Indian corporation based in Gurgaon, Haryana, India and has a place of business at 600 College Road East, Princeton, New Jersey. On further information and belief, Defendant Ranbaxy Laboratories Limited is engaged in the business of developing, manufacturing, and selling various pharmaceutical products, many of which are sold in New Jersey.

4. On information and belief, Defendant Ranbaxy Pharmaceuticals Inc. is a New Jersey Corporation with its principal place of business at 600 College Road East, Princeton, New Jersey. On further information and belief, Defendant Ranbaxy Pharmaceuticals Inc. is engaged in the business of developing, manufacturing, and selling various pharmaceutical products, many of which are sold in New Jersey.

NATURE OF THE ACTION

5. This is an action for patent infringement arising under the Patent Laws of the United States, 35 U.S.C. § 1 et seq., and seeking injunctive relief under 35 U.S.C. §§ 281-283.

JURISDICTION AND VENUE

6. This Court has subject matter jurisdiction over this controversy under 28 U.S.C. §§ 1331 and 1338(a), and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

7. This Court may declare the rights and other legal relations of the parties pursuant to 28 U.S.C. §§ 2201 and 2202 because this is a case of actual controversy within the Court's jurisdiction.

8. This Court has personal jurisdiction over Defendants because of, *inter alia*, Defendants' systematic, purposeful and continuous contacts in this District, Defendant Ranbaxy Pharmaceuticals Inc.'s principal place of business in this District, and Defendant Ranbaxy Laboratories Limited's availment of the privilege of doing business in this District through its subsidiary and agent Defendant Ranbaxy Pharmaceuticals Inc.

9. Venue is proper in this judicial district based on 28 U.S.C. § 1400(b) and/or 28 U.S.C. § 1391(b), (c), and (d).

FACTUAL BACKGROUND

The Patents in Suit

10. Teva Ltd. is the owner of all right, title and interest in United States Patent Nos. 6,699,997 ("the '997 Patent"), 6,710,184 ("the '184 Patent"), 7,056,942 ("the '942 Patent"), and 7,126,008 ("the '008 Patent"; collectively, "the patents in suit") relating to, *inter alia*, various forms of a chemical compound known as carvedilol and processes for preparing various forms of carvedilol. One polymorphic form of carvedilol is known as "Form II."

11. The '997 Patent was duly and legally issued by the United States Patent and Trademark Office ("PTO") on March 2, 2004 for an invention entitled "Carvedilol." A copy of the '997 Patent is attached as Exhibit A.

12. The '008 Patent was duly and legally issued by the PTO on October 24, 2006 for an invention entitled "Carvedilol." A copy of the '008 Patent is attached as Exhibit B.

13. The '997 and '008 Patents claim processes for preparing carvedilol.

14. The '184 Patent was duly and legally issued by the PTO on March 23, 2004 for an invention entitled "Crystalline Solids of Carvedilol and Processes for Their Preparation." A copy of the '184 Patent is attached as Exhibit C.

15. The '184 Patent claims processes for preparing carvedilol Form II.

16. The '942 Patent was duly and legally issued by the PTO on June 6, 2006 for an invention entitled "Carvedilol." A copy of the '942 Patent is attached as Exhibit D.

17. The '942 Patent claims, *inter alia*, a hydrate form of carvedilol hydrochloride.

GlaxoSmithKline's Exclusivity

18. Carvedilol is a pharmaceutical compound used in the treatment of congestive heart failure. It is the active pharmaceutical ingredient ("API") in the product sold by GlaxoSmithKline ("GSK") under the trade name COREG®. COREG® is included in the United States Food and Drug Administration's ("FDA") list of "Approved Drug Products With Therapeutic Equivalence Evaluations," also known as the "Orange Book." Approved drugs listed in the Orange Book may be used as the basis of a later applicant's Abbreviated New Drug Application to obtain approval of the applicant's generic drug product under 21 U.S.C. § 355(j).

19. The carvedilol compound is disclosed and claimed in U.S. Patent No. 4,503,067 ("the '067 Patent"), which is owned by GSK. The '067 Patent is listed in the FDA's Orange Book in association with COREG®. The '067 Patent expired on March 5, 2007.

20. Pursuant to 21 U.S.C. § 355a, GlaxoSmithKline was awarded a six-month period of pediatric exclusivity following the expiration of the '067 Patent. GlaxoSmithKline's pediatric exclusivity period extends from March 5, 2007 to September 5, 2007. Pursuant to this exclusivity, the FDA cannot grant final approval to any Abbreviated New Drug Application ("ANDA") holders for carvedilol during that period. The FDA may grant final approval to ANDA holders beginning immediately upon expiration of GSK's pediatric exclusivity period.

Defendants' Imminent Infringement of the Patents in Suit

21. On information and belief, Defendants submitted ANDA No. 76-989 to the FDA, requesting approval to market a generic version of COREG® in 3.125, 6.25, 12.5, and 25 mg dosage strengths.

22. Defendants have received tentative approval of their ANDA from the FDA. On information and belief, final approval of Defendants' ANDA is expected to be granted shortly after the expiration of GSK's pediatric exclusivity period on September 5, 2007. Once Defendants receive final approval of their ANDA, they will be able to market generic carvedilol tablets in the United States.

23. Under the Hatch-Waxman Act, ANDA holders must provide detailed information to the FDA about how the API to be used in their proposed generic products will be made. ANDA holders may make the API themselves or, instead, may purchase the API from a supplier. When an ANDA holder intends to purchase API from a supplier to use in the proposed product, the ANDA holder may reference a Drug Master File ("DMF") submitted to the FDA by that supplier, instead of providing process information in the ANDA. Plaintiffs have been unable to obtain from a public source any information regarding whether Defendants will make or purchase the API to be used in their proposed products.

24. On information and belief, Defendants plan and intend to make carvedilol API or to purchase carvedilol API from a third party DMF holder, to use in the manufacture of their proposed generic carvedilol tablets ("Defendants' tablets").

25. On information and belief, Defendants plan and intend to engage in the commercial importation, manufacture, use, sale and/or offer for sale of generic carvedilol tablets in the United States.

26. On information and belief, Defendants plan and intend to engage in the activities described in paragraph 25 immediately upon receiving final approval of their ANDA from the FDA and said approval will occur shortly after GSK's pediatric exclusivity period expires.

27. On information and belief, Defendants plan and intend to engage in the activities described in paragraph 25 prior to the expiration of the patents in suit.

28. On information and belief, Defendants' tablets will include carvedilol API that infringes or will infringe one or more claims of the patents in suit, and/or that is or will be made by a process that infringes one or more claims of the patents in suit. Accordingly, Defendants' plans and intentions to make and sell carvedilol tablets in the United States constitute imminent, threatened acts of infringement under 35 U.S.C. § 271, which give rise to an actual controversy over which the Court may exercise jurisdiction.

29. Plaintiffs have made a reasonable effort to determine the chemical composition of the carvedilol API to be used in Defendants' tablets, as well as the process by which the carvedilol API to be used in Defendants' tablets is or will be made. On May 8, 2007, Teva USA notified Defendant Ranbaxy Laboratories Limited of the existence of the patents in suit and sought information allowing Plaintiffs to ascertain whether Defendants' tablets and/or the API to be used in Defendants' tablets fall within the scope of one or more of the patents in suit, and/or whether the API to be used in Defendants' tablets is made pursuant to a process that falls within the scope of one or more of the patents in suit. In particular, Teva USA requested a detailed description of all processes that will be used to manufacture Defendants' tablets, all processes that will be used to make the API to be used in Defendants' tablets, samples of Defendants' tablets, and samples of the API to be used in Defendants' tablets. Teva USA offered to enter into

a confidentiality agreement to protect the confidentiality of any information disclosed by Defendants. Pursuant to this offer, Teva USA supplied a proposed confidentiality agreement.

30. Defendants have not provided to Teva USA samples of Defendants' tablets or of the API to be used in Defendants' tablets, or the detailed information requested regarding the processes by which Defendants' tablets are manufactured or the API to be used in the tablets is made, despite Teva USA's offer of confidentiality. Further, Plaintiffs have been unable to obtain from a public source samples of Defendants' tablets or the API to be used in their manufacture.

31. Without the requested information, Plaintiffs are unable to determine whether Defendants' tablets, or the API to be used in Defendants' tablets, infringes one or more compounds claimed in the patents in suit, or whether the processes by which the API is made infringe one or more methods claimed in the patents in suit. For this reason, Plaintiffs cannot conclusively determine whether Defendants infringe each of the patents in suit unless and until Defendants provide samples of its tablets and samples of the API to be used in their manufacture and discloses to Plaintiffs the processes by which the tablets and API are made.

32. In the absence of a sufficient response from Defendants, Plaintiffs have no choice but to resort to the judicial process and the aid of discovery to obtain, under appropriate judicial safeguards, the information required to confirm their beliefs as to infringement and to present the Court evidence that Defendants will infringe the patents in suit.

33. As a direct and proximate consequence of the planned and intended infringement by Defendants, Plaintiffs will be injured in their business and property rights unless the infringement is enjoined by the Court, and will suffer injury for which they are entitled to relief.

COUNT I

Declaratory Judgment of Patent Infringement

34. Plaintiffs repeat and reallege Paragraphs 1 through 33 of the Complaint as if fully set forth herein.

35. On information and belief, the importation, manufacture, use, sale and/or offer for sale by Defendants of their carvedilol tablets pursuant to ANDA No. 76-989 will infringe, either literally or under the doctrine of equivalents, one or more claims of the '997, '184, '942, and/or '008 Patents, or will contribute to or induce such infringement, under 35 U.S.C. § 271.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs Teva Ltd. and Teva USA respectfully request a judgment from the Court:

1. Declaring that the '997, '184, '942, and '008 Patents are valid and enforceable;

2. Declaring that Defendants will infringe, either literally or under the doctrine of equivalents, one or more claims of the '997, '184, '942, and/or '008 Patents, or will contribute to or induce such infringement, under 35 U.S.C. § 271;

3. Declaring that Defendants' infringement will be willful and that this is an exceptional case under 35 U.S.C. § 285;

4. Permanently enjoining Defendants, their officers, agents, servants and employees, and those persons in active concert or participation with any of them, from infringing the '997, '184, '942, and '008 Patents;

5. Awarding Plaintiffs their attorneys' fees, costs, and expenses; and

6. Awarding Plaintiffs such other relief that the Court deems proper, just and equitable.

LITE DEPALMA GREENBERG & RIVAS, LLC

Dated: June 21, 2007

Allyn Z. Lite
Michael E. Patunas
Two Gateway Center, 12th Floor
Newark, New Jersey 07102
(973) 623-3000
Attorneys for Plaintiffs Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc.